We are live on
!
Find out more
BIA
Biondo Investment Advisors Portfolio holdings
AUM
$780M
1-Year Est. Return
21.03%
This Fund
S&P 500
This Quarter
Est. Return
+14.25%
1 Year Est. Return
+21.03%
3 Year Est. Return
+89.14%
5 Year Est. Return
+116.93%
10 Year Est. Return
+716.27%
AUM
$421M
AUM Growth
+$24.5M
(+6.2%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
54.25%
Holding
87
New
6
Increased
51
Reduced
19
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$3.45M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$3.22M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$2.74M |
| 4 |
Axogen
AXGN
|
+$2.31M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$1.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$14M |
| 2 |
Diamondback Energy
FANG
|
+$9.77M |
| 3 |
JPM.WS
JPMorgan Chase
JPM.WS
|
+$5.04M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$3.73M |
| 5 |
Core Laboratories
CLB
|
+$2.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.18% |
| 2 | Financials | 13.34% |
| 3 | Technology | 13.1% |
| 4 | Consumer Discretionary | 7.56% |
| 5 | Communication Services | 5.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Edwards Lifesciences
EW
$51.5B
| $300K | 0.07% |
5,175
+150
| +3% | +$7.34K |
|
|
BLUE
77
DELISTED
bluebird bio
BLUE
| $247K | 0.06% |
131
+4
| +3% | +$8.26K |
|
78
Ulta Beauty
ULTA
$23.2B
| $227K | 0.05% |
+805
| New | +$205K |
|
79
Bank of America
BAC
$441B
| $205K | 0.05% |
+6,950
| New | +$212K |
|
|
GCVRZ
80
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $7K | ﹤0.01% |
13,675
-250
| -2% | -$134 |
|
|
81
Core Laboratories
CLB
$513M
| – | – |
-22,082
| Closed | -$2.79M |
|
|
82
Diamondback Energy
FANG
$53.1B
| – | – |
-74,232
| Closed | -$9.77M |
|
|
83
Meta Platforms (Facebook)
META
$1.5T
| – | – |
-72,130
| Closed | -$14M |
|
84
Tesla
TSLA
$1.26T
| – | – |
-45,600
| Closed | -$1.04M |
|
85
Wells Fargo
WFC
$265B
| – | – |
-3,759
| Closed | -$210K |
|
|
JPM.WS
86
DELISTED
JPMorgan Chase
JPM.WS
| – | – |
-79,480
| Closed | -$5.04M |
|
|
WPZ
87
DELISTED
Williams Partners L.P.
WPZ
| – | – |
-8,563
| Closed | -$348K |
|
Similar funds
LA
SG
RTM
TCMX
QCMNJ
TIS
MO
NCM
Biondo Investment Advisors's Q3 2018 Portfolio in Review
As of Q3 2018, Biondo Investment Advisors held 87 positions worth $421M, up 6.2% from $397M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Biondo Investment Advisors withdrew a net $21.7M in Q3 2018, closing 7 positions and reducing 19 holdings. Its most notable exit was Meta Platforms (Facebook), an estimated $14M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 35% a quarter earlier, followed by Financials and Technology.
Against the trend, Biondo Investment Advisors opened a new position in Intercept Pharmaceuticals, Inc. worth $3.84M.
- Biondo Investment Advisors's largest Q3 2018 buy was Intercept Pharmaceuticals, Inc.: 30,395 shares worth $3.84M.
- Biondo Investment Advisors added most to Regeneron Pharmaceuticals in Q3 2018, an estimated $3.45M increase.
- Biondo Investment Advisors's biggest Q3 2018 reduction was Bristol-Myers Squibb, cutting an estimated $3.73M.
- Biondo Investment Advisors fully exited Meta Platforms (Facebook) in Q3 2018, selling an estimated $14M.
- Biondo Investment Advisors's ten largest holdings make up 54% of its $421M portfolio in Q3 2018.
- Biondo Investment Advisors opened 6 new positions and closed 7 in Q3 2018.
- Biondo Investment Advisors's portfolio value rose 6.2% quarter-over-quarter to $421M.
Based on Biondo Investment Advisors's 13F filing for Q3 2018, filed 7 Nov 2018.